May 2 |
Alnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44M
|
May 2 |
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
|
May 1 |
Alnylam Pharmaceuticals Q1 2024 Earnings Preview
|
May 1 |
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
|
Apr 30 |
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
|
Apr 30 |
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
|
Apr 19 |
How Is The Market Feeling About Alnylam Pharmaceuticals?
|
Apr 18 |
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
|
Apr 8 |
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
|
Apr 8 |
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
|